Tetragenex Pharmaceuticals, Inc. recently announced that its common stock has begun trading on the OTC Bulletin Board under the symbol TTRX.OB. Previously, the company had been privately held. The company is focused on discovering, developing, and commercializing proprietary pharmaceutical products that treat serious diseases which are not able to be treated through current therapies.
Martin Schacker, Chief Executive Officer of Tetragenex, remarked, “As Tetragenex continues to report impressive results from Phase II human clinical trials of our flagship drug, the novel antidepressant nemifitide, as well as forge ahead with our other drug development initiatives, we felt it was important to make our common stock available to those interested in participating in what promises to be a period of dynamic opportunity for the company. We believe that including our common stock for quotation on the OTC Bulletin Board will increase the liquidity of our common stock and make it more readily available to potential investors.”
Let us hear your thoughts below: